AX
AXIM.US Axim Biotechnologies Inc
- Market cap
- USD 1.05M
- P/E
- -
- P/B
- 2.86x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is AXIM.US undervalued?
Graham numberThe Graham number of Axim Biotechnologies Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Axim Biotechnologies Inc fundamental analysis
No fundamental analysis for Axim Biotechnologies Inc yet.
Axim Biotechnologies Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Axim Biotechnologies Inc
AXIM Biotechnologies, Inc. develops diagnostic healthcare solutions for ophthalmological conditions. It develops and commercializes two point-of-care diagnostic tests to assist eye-care physicians in detecting and quantifying biomarkers associated with aqueous deficient dry eye disease and non-specific allergic conjunctivitis, including ocular total immunoglobulin E allergy test and lactoferrin ADDE test. It also operates a full-service center for custom biomarker and biopha…
Full company profileAxim Biotechnologies Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Axim Biotechnologies Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 47.1K | 47.6K | 196K | 799K | -109K | 60.5K | 8.88K | 39.5K | 70.5K | - | 784K |
| Gross Profit | -107K | 4.72K | 187K | 224K | -16.0K | 60.5K | -417K | 39.5K | -369K | -427K | 354K |
| Operating Income | -3.76M | -3.15M | -5.04M | -6.51M | -4.95M | -7.99M | -4.65M | -2.75M | -1.76M | -1.32M | -581K |
| EBITDA | -5.51M | -3.14M | -5.16M | -2.67M | -4.93M | -13.2M | -3.94M | -6.43M | -2.44M | -892K | -168K |
| Net Income | -5.81M | -4.17M | -6.75M | -6.77M | -6.73M | -16.5M | -5.96M | -8.06M | -3.51M | -1.04M | 253K |
| EPS | -0.14 | -0.08 | -0.12 | -0.11 | -0.06 | -0.13 | -0.04 | -0.04 | -0.01 | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 1.45M | 2.19M | 2.09M | 1.69M | 11.3M | 5.32M | 4.21M | 4.12M | 3.45M | 2.88M | 3.29M |
| Total Liabilities | 3.82M | 8.48M | 8.17M | 8.45M | 9.75M | 7.66M | 9.04M | 11.8M | 13.9M | 14.2M | 14.5M |
| Shareholders' Equity | -2.37M | -6.28M | -6.08M | -6.76M | 1.57M | -2.34M | -4.83M | -7.66M | -10.4M | -11.4M | -11.2M |
| Cash & Short-term Investments | 713K | 2.06M | 1.96M | 753K | 457K | 453K | 47.3K | 156K | 245.00 | 4.97K | 10.4K |
| Total Debt | 1.77M | 6.40M | 5.87M | 6.10M | 6.31M | 6.72M | 5.66M | 5.89M | 6.64M | 7.78M | 7.78M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.29M | -3.08M | -4.85M | -5.02M | -3.22M | -2.49M | -2.04M | -1.03M | -855K | -686K | 1.17M |
| Capital Expenditure | 0.00 | 97.3K | 97.3K | 97.3K | 97.3K | 50.5K | 8.71K | 0.00 | 2.84K | 0.00 | 10.00 |
| Free Cash Flow | -1.29M | -3.08M | -4.85M | -5.02M | -3.31M | -2.54M | -2.05M | -1.03M | -858K | -686K | 1.17M |
| Ratios | |||||||||||
| ROE | - | - | - | - | -429.9% | - | - | - | - | - | - |
| ROA | -400.9% | -190.1% | -323.3% | -400.2% | -59.5% | -310.3% | -141.4% | -195.5% | -101.9% | -36.3% | 7.7% |
| Net Profit Margin | -12,346.0% | -8,761.7% | -3,453.0% | -847.0% | - | -27,320.8% | -67,120.7% | -20,395.0% | -4,985.2% | - | 32.2% |
| Debt to Equity | - | - | - | - | 4.03x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Axim Biotechnologies Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | USD 1.48M | 0.03 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Axim Biotechnologies Inc
- Insiders 22.39%
- Institutions 0.00%
- Public & others 77.61%
- Shares outstanding 350M
- Free float 244M
Axim Biotechnologies Inc company profile
- Company name
- Axim Biotechnologies Inc
- Ticker
- AXIM.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 6
- Fiscal year end
- December
- Address
- 6191 Cornerstone Court, East, San Diego, CA, United States, 92121
- Phone
- 858 923 4422
- Website
- aximbiotech.com
About Axim Biotechnologies Inc
AXIM Biotechnologies, Inc. develops diagnostic healthcare solutions for ophthalmological conditions. It develops and commercializes two point-of-care diagnostic tests to assist eye-care physicians in detecting and quantifying biomarkers associated with aqueous deficient dry eye disease and non-specific allergic conjunctivitis, including ocular total immunoglobulin E allergy test and lactoferrin ADDE test. It also operates a full-service center for custom biomarker and biopharmaceutical research, custom assay development, clinical sample testing, and precision data delivery. In addition, the company develops a line of novel diagnostics for early cancer detection, response to treatment, and recurrence monitoring, as well as COVID-19 rapid diagnostic tools. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.
Axim Biotechnologies Inc management
8- Ms. Catalina Valencia J.D.CEO, President & Director · born 1950
- Mr. Robert T. MalasekCFO & Secretary · born 1968
- Mr. Kurt PhinneyChief Operating Officer · born 1973
- Mr. Jeffrey A. BusbyHead of Global Sales
- Dr. Sergei A. Svarovsky M.B.A., Ph.D.Chief Scientific Officer
- Dr. Douglas Lake Ph.D.Chief Clinical Officer of Sapphire Biotech, Inc.
- Dr. Joseph Tauber M.D.Chief Medical Officer & Chairman of the Medical Advisory Board · born 1957
- Dr. Maria J. Gonzalez Moa Ph.D.Vice President of Product Development - Sapphire Biotech, Inc.